-
From Global Follower to International Mentor Award: Professor Guohua Zeng Receives One of the Highest Honors in Urology
01. A Historic Breakthrough for Chinese Urology The Ralph Clayman Mentor Award is one of the top honors in the field of urology, recognizing individuals who have made lasting and…
-
Professor Aili Zhang Interprets Immunotherapy and Targeted–Immunotherapy Combination Strategies for Renal Cell Carcinoma
2025 Pujiang Uro-Oncology Academic Conference 01. Postoperative Adjuvant Therapy: Pembrolizumab Establishes a New Milestone in Overall Survival Benefit For a long time, postoperative adjuvant therapy for high‑risk renal cell carcinoma…
-
ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27 in Kumamoto, Japan. This prestigious event brought together leading experts from around the world to discuss cutting-edge developments in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the highlights of this…
-
CSCO 2025 │ Professor Lili Mao: Updates to Perioperative Therapy in the 2025 CSCO Melanoma Guidelines
Q1. Key Conceptual Shifts in Perioperative Therapy Prof. Lili Mao: This year’s CSCO Melanoma Guidelines introduce several important updates regarding perioperative treatment. For cutaneous melanoma, we have added recommendations for…
-
Professor Haibo Wang: Advancing Comprehensive Breast Cancer Care through Innovation and Multidisciplinary Collaboration
Key Highlights of the 2025 Conference Prof. Haibo Wang: This year’s conference retained its hallmark sessions, such as expert debates and the signature “Langya Forum,” while introducing several new and…
-
“Those Who Fail to See the Whole Cannot Govern the Parts” — Professor Qiang Liu Shares New Perspectives on Neoadjuvant Therapy for Breast Cancer
From “Blind Box” to “Scientific Fortune-Telling” to “Changing Destiny” At this year’s CSCO breast cancer session, I delivered a talk titled ‘New Perspectives on Neoadjuvant Therapy for Breast Cancer: Those…
-
CSCO Journey │ Professor Man Li: CSCO Member No. 168, Witness to China’s Leap Forward in Clinical Oncology
Q1. Growth with CSCO and Its Influence Prof. Man Li: I started working in 1996 and became a member of the CSCO family in 1997. My membership number is 19970168—quite…
-
Professor Fei Ma: Ushering in a New Era of ‘Chemotherapy + Immunotherapy + Targeted Therapy’ for Advanced Triple-Negative Breast Cancer
Q1. The Synergy of Chemotherapy, Immunotherapy, and Targeted Therapy Prof. Fei Ma: Triple-negative breast cancer is a subtype of breast cancer, accounting for about 15% of all cases. Among them,…
Connecting Medical Expertise through Media